Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.41
+$0.11 · +4.78%
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Latest quote
$2.41
+$0.11 · +4.78%
After-hours
$2.43
+$0.02 · +0.83%
Oct 9, 6:09 PM ET
Regular session · ET · Market data may be delayed.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Day range
Current $2.41
52-week range
Current $2.41
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
47
Fair Value
Sentiment
50
Mixed
Risk
41
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Day range
Current $2.41
52-week range
Current $2.41
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$14.00
480.91% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 7, 2024 | 1:10 | — | — |
Effective Oct 7, 2024
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.19M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1.34M0.00%78.18B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1.11M0.00%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO547.73K0.00%18B USD0.06%$112.66+0.50%
iShares Russell 2000 Value ETFIWN520.39K—13.83B USD0.24%$210.87-0.04%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED214.32K0.66%32.26M USD0.44%$33.8094+2.13%
iShares Micro-Cap ETFIWC190.75K0.01%1.32B USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM120K0.10%116.54M USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
